BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $352,960.20 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 17,604 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the completion of the transaction, the executive vice president now owns 284,442 shares of the company’s stock, valued at $5,703,062.10. The trade was a 5.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

BioLife Solutions Trading Up 11.5 %

Shares of BLFS stock opened at $25.01 on Thursday. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -23.59 and a beta of 1.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a fifty-two week low of $11.91 and a fifty-two week high of $28.88. The firm’s 50 day moving average price is $23.96 and its two-hundred day moving average price is $22.88.

Analysts Set New Price Targets

A number of research analysts have recently commented on BLFS shares. Northland Securities upped their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. TD Cowen boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. HC Wainwright dropped their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday. Finally, Craig Hallum boosted their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and an average price target of $27.50.

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in BioLife Solutions by 11.5% during the 1st quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock worth $53,208,000 after purchasing an additional 296,727 shares during the period. Fred Alger Management LLC boosted its position in shares of BioLife Solutions by 6.0% in the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after buying an additional 88,840 shares during the period. State Street Corp grew its stake in shares of BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of BioLife Solutions by 9.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock valued at $17,034,000 after buying an additional 66,422 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.